Phosphosulindac (OXT-328) prevents and reverses chemotherapy induced peripheral neuropathy in mice
Basu A, Yang J, Tsirukis V, Loiacono A, Koch G, Khwaja I, Krishnamurthy M, Fazio N, White E, Jha A, Shah S, Takmil C, Bagdas D, Demirer A, Master A, Natke E, Honkanen R, Huang L, Rigas B. Phosphosulindac (OXT-328) prevents and reverses chemotherapy induced peripheral neuropathy in mice. Frontiers In Neuroscience 2024, 17: 1240372. PMID: 38347876, PMCID: PMC10860339, DOI: 10.3389/fnins.2023.1240372.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyAnticancer effect of paclitaxelEffects of paclitaxelAllodynia scoresCold allodyniaPeripheral neuropathyInduces chemotherapy-induced peripheral neuropathyChemotherapeutic efficacy of paclitaxelLewis lung carcinoma xenograftsPrevent chemotherapy-induced peripheral neuropathyHind paw of miceAnticancer effectsTreat chemotherapy-induced peripheral neuropathyVon Frey testLevels of IL-6Chemotherapy induced peripheral neuropathyEfficacy of paclitaxelPaw of miceLung cancer xenograftsLung carcinoma xenograftsMale C57BL/6 J miceCell linesSide effects of chemotherapyEffects of chemotherapyApparent side effects